The company’s surgical specialties business quarterly revenues reached $8.5 million, an 18 percent increase, while its bone graft substitutes and general orthopedic business quarterly revenues reached $7.0 million, a 12 percent increase. RTI Biologics’ sports medicine business line also achieved $13.3 million, a 10 percent increase over the second quarter of 2011.
More Articles on Orthopedic Devices:
Global Spinal Devices and Biologics Market to Grow 6.9% Annually
DePuy Synthes Spine Systems Receive FDA Approval to Treat Scoliosis
Symmetry Medical Announces 2Q Revenue of $102.3M, 8% Increase
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
